New indication for Celebrex

The licence for Celebrex (celecoxib) has been extended to include symptomatic relief in the treatment of ankylosing spondylitis. Celebrex was already licensed for symptomatic relief in the treatment of osteoarthritis and rheumatoid arthritis.

The recommended daily dose of Celebrex for patients with ankylosing spondylitis is 200mg taken once daily or in two divided doses. A maximum dose of 400mg daily may be required in some patients. Therapeutic benefit should be assessed after two weeks of use.

Further information: Pharmacia 01304 616161

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more